ZEISS Medical Technology and Boehringer have entered into a long-term strategic collaboration to develop predictive analytics to enable early detection of eye diseases and more personalised treatments to prevent vision loss for people with serious eye diseases.
The partnership brings together their leading expertise in ophthalmological technology, data analytics, algorithms and the development of first-in-class treatments to detect early and treat retinal diseases before irreversible vision loss occurs.
The new partnership will focus on identifying markers of early stages of retinal diseases by leveraging ZEISS Medical Technology’s cloud-connected devices and AI-assisted analysis of massive image data sets. This will provide a basis for clinical studies for development of more personalised and precise treatments of early stages of chronic retinal disease as well as earlier detection and prediction capabilities to preserve vision through new treatment pathways.
The new partnership will focus on identifying markers of early stages of retinal diseases by leveraging ZEISS Medical Technology’s cloud-connected devices and AI-assisted analysis of massive image data sets
Data Aggregation at Scale
As a leading pioneer of science in optics for more than 100 years, ZEISS’s medical expertise and digital leadership is foundational to the ZEISS Medical Ecosystem and its digitally connected workflows, which are generating millions of data points every day. This connected and secure architecture integrates diagnostic and therapeutic devices supported by a cloud-based platform in which data aggregation, automation and AI analytics can be harnessed to help drive new discoveries to address the clinical challenges facing healthcare professionals and ophthalmologists today. The ZEISS Medical Ecosystem is powered by the ZEISS Health Data Platform, designed to facilitate massive data aggregation at scale, enabling new forms of partnerships focused on leveraging that data to generate new, transformative insights.
Boehringer Ingelheim has a leading understanding of disease biology aiming at a paradigm change in retinal health through earlier detection and intervention to achieve meaningful improvements in patient outcomes. Over the past decade, Boehringer Ingelheim has built a diverse pipeline, which focuses on three priority areas to address retinal conditions – the preservation of vascular function, targeting inflammation and neuroprotection.
Precision Therapies to be Developed
“Our partnership with ZEISS Medical Technology will allow us to develop precision therapies delivering the right treatment for the right patient at the right time to prevent vision loss by intervening before irreversible damage occurs. It is part of our commitment to champion early detection and treatment and will contribute to transforming the lives of people with serious eye disease,” said Ulrike Graefe-Mody, Ph.D., Head of Retinal Health at Boehringer Ingelheim.
